Ferring Pharmaceuticals: Ulcer trials

The registry lists 18 Ulcer studies with Ferring Pharmaceuticals as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 3 7Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)CompletedNCT02522780Phase 3Results posted
• Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)CompletedNCT02522767Phase 3Results posted
• Canadian Active & Maintenance Modified Pentasa StudyCompletedNCT00603733Phase 3Results posted
• A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative ColitisWithdrawnNCT06260267Phase 1
• Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in KoreaCompletedNCT04499495
• Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)CompletedNCT04340895Not applicable
• To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative ColitisCompletedNCT03412682Phase 3
• Effectiveness of Cortiment® in Patients With Ulcerative ColitisCompletedNCT02586259
• An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension PhaseCompletedNCT02368717Phase 3
• Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis TreatmentCompletedNCT02261636
• Mesalazine (PENTASA®) in Ulcerative ColitisCompletedNCT01517607
• Tolerability of Pentasa Sachet in Patients With Ulcerative ColitisCompletedNCT01517594
• Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative ColitisCompletedNCT01387698
• User Surveillance in Ulcerative ColitisCompletedNCT01363453
• A Study of Pentasa in Patients With Ulcerative ColitisCompletedNCT01104753
• Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.CompletedNCT00737789Phase 3
• Pentasa Once Daily in Ulcerative Colitis for Maintenance of RemissionCompletedNCT00209300Phase 3
• Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative ColitisTerminatedNCT00209287Phase 4